Pheon Therapeutics Enhances Leadership with Oncologist Dr. Samuel Blackman

Pheon Therapeutics Enhances Leadership with Dr. Samuel Blackman

Pheon Therapeutics, a leader in the clinical development of Antibody-Drug Conjugates (ADCs), has announced a significant addition to its leadership team. The company has appointed Dr. Samuel Blackman, an esteemed expert in oncology research and development, to its Board of Directors. This strategic move reflects Pheon's commitment to advancing its pioneering ADCs aimed at treating a variety of challenging cancers.

Dr. Blackman, who is recognized for his robust background in both clinical and industrial settings, joins Pheon as an independent, Non-Executive Director. His illustrious career includes notable positions as an Entrepreneur-in-Residence at Google Ventures and as the former head of R&D at Day One Biopharmaceuticals, where he focused on developing targeted therapies for patients across all age groups suffering from serious illnesses. His diverse experience spans from giant pharmaceutical companies like Merck and GlaxoSmithKline to innovative startups like Mavupharma and Seattle Genetics.

The CEO of Pheon, Dr. Cyrus Mozayeni, expressed enthusiasm about Dr. Blackman's appointment, highlighting his deep expertise in oncology drug development as vital for the company’s goals. Dr. Mozayeni stated, "Sam brings deep expertise in oncology drug development to the Board as we head into our next exciting chapter as a clinical-stage company. With a proven track record of innovation across industry and clinical research, Sam will be an invaluable addition to our team."

Pheon is currently focused on advancing its clinical ADC programs, specifically targeting a novel and first-in-class entity that displays high expression levels in multiple solid tumors with substantial unmet medical needs. This strategy aims to promote precision medicine while minimizing toxicity to healthy tissues. The inclusion of Dr. Blackman’s expertise is expected to provide essential strategic guidance as Pheon accelerates its R&D and clinical operations, particularly with its lead ADC candidate entering Phase 1 clinical trials.

In addition to his scientific endeavors, Dr. Blackman has made a name for himself as a talented storyteller, winning two GrandSLAMs at The Moth and showcasing his ability to communicate effectively, which is essential in both the medical and corporate sectors. His skills are complemented by his involvement with various organizations, serving on boards such as Bonum Therapeutics and The Pediatric Brain Tumor Foundation.

Dr. Blackman remarked on his new role, saying, "Pheon is pushing the boundaries of what is possible in ADC science, and this deeply resonates with my approach to innovation. I am honored to join at this critical inflection point and look forward to supporting the team as it advances its programs through the clinic."

To sum up, the addition of Dr. Samuel Blackman to Pheon Therapeutics' Board marks a promising step forward in the company’s mission to develop breakthrough therapies for patients facing life-threatening cancers. With his vast knowledge and experience, Pheon is poised to enhance its clinical programs and achieve pivotal breakthroughs in oncology treatment.

About Pheon Therapeutics

Pheon Therapeutics is a clinical-stage firm specializing in Antibody Drug Conjugates (ADCs) aimed at addressing hard-to-treat solid tumors. The company is backed by leading healthcare investors and boasts a team equipped with extensive expertise in the fields of ADC engineering, clinical trials, and management. For more information about Pheon and its innovative therapies, visit www.pheontx.com.